Combination of | |
---|---|
Clindamycin | Lincosamide antibacterial |
Adapalene | Retinoid |
Benzoyl peroxide | Oxidizing agent |
Clinical data | |
Trade names | Cabtreo |
AHFS/Drugs.com | Cabtreo |
License data | |
Routes of administration | Topical |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Clindamycin/adapalene/benzoyl peroxide, sold under the brand name Cabtreo, is a fixed-dose combination medication used for the treatment of acne. [2] It contains clindamycin 1.2%, as the phosphate, a lincosamide antibacterial; adapalene 0.15%, a synthetic retinoid; and benzoyl peroxide 3.1%, an oxidizing agent. [2] It is applied to the skin. [2]
Clindamycin/adapalene/benzoyl peroxide was approved for medical use in the United States in October 2023. [2] [3] It is the first triple-combination topical acne treatment approved by the US Food and Drug Administration. [3]